Alice Torres

Dr. Alice Torres


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
TAThalita Souza Arantes
Thalita Souza Arantes
Rodrigo RodriguesRodrigo Rodrigues
Rodrigo Rodrigues
LSLudmila Karen dos Santos Silva
Ludmila Karen dos Santos Silva
GOGraziele Pereira Oliveira
Graziele Pereira Oliveira
HSHelton Luís de Souza
Helton Luís de Souza
JAJonatas Abrahao
Jonatas Abrahao
Triggering the amoebal phagocytosis process is a sine qua non condition for most giant viruses to initiate their replication cycle and consequently to promote their progeny formation. It is well known that the amoebal phagocytosis process requires the recognition of particles of >500 nm, and most amoebal giant viruses meet this requirement, such as mimivirus, pandoravirus, pithovirus, and mollivirus. However, in the context of the discovery of amoebal giant viruses in the last decade, Marseillevirus marseillevirus (MsV) has drawn our attention, because despite its ability to successfully replicate in Acanthamoeba , remarkably it does not fulfill the >500-nm condition, since it presents an ∼250-nm icosahedrally shaped capsid. We deeply investigated the MsV cycle by using a set of methods, including virological, molecular, and microscopic (immunofluorescence, scanning electron microscopy, and transmission electron microscopy) assays. Our results revealed that MsV is able to form giant vesicles containing dozens to thousands of viral particles wrapped by membranes derived from amoebal endoplasmic reticulum. Remarkably, our results strongly suggested that these giant vesicles are able to stimulate amoebal phagocytosis and to trigger the MsV replication cycle by an acidification-independent process. Also, we observed that MsV entry may occur by the phagocytosis of grouped particles (without surrounding membranes) and by an endosome-stimulated pathway triggered by single particles. Taken together, not only do our data deeply describe the main features of MsV replication cycle, but this is the first time, to our knowledge, that the formation of giant infective vesicles related to a DNA virus has been described. IMPORTANCE Triggering the amoebal phagocytosis process is a sine qua non condition required by most giant viruses to initiate their replication cycle. This process requires the recognition of particles of >500 nm, and many giant viruses meet this requirement. However, MsV is unusual, as despite having particles of ∼250 nm it is able to replicate in Acanthamoeba . Our results revealed that MsV is able to form giant vesicles, containing dozens to thousands of viral particles, wrapped in membranes derived from amoebal endoplasmic reticulum. Remarkably, our results strongly suggest that these giant vesicles are able to stimulate phagocytosis using an acidification-independent process. Our work not only describes the main features of the MsV replication cycle but also describes, for the first time to our knowledge, the formation of huge infective vesicles in a large DNA viruses.

1 July 2009 in Journal of Virology
Verified
Journal Article
Closed access
JSJamária A. P. Soares
Jamária A. P. Soares
FLFlávia G. G. Leite
Flávia G. G. Leite
LALuciana G. Andrade
Luciana G. Andrade
ATAlice Torres
Alice Torres
LSLirlândia P. De Sousa
Lirlândia P. De Sousa
CBCláudio A. Bonjardim
Cláudio A. Bonjardim
Viral manipulation of the transduction pathways associated with key cellular functions such as actin remodeling, microtubule stabilization, and survival may favor a productive viral infection. Here we show that consistent with the vaccinia virus (VACV) and cowpox virus (CPXV) requirement for cytoskeleton alterations early during the infection cycle, PBK/Akt was phosphorylated at S473 [Akt(S473-P)], a modification associated with the mammalian target of rapamycin complex 2 (mTORC2), which was paralleled by phosphorylation at T308 [Akt(T308-P)] by PI3K/PDK1, which is required for host survival. Notably, while VACV stimulated Akt(S473-P/T308-P) at early (1 h postinfection [p.i.]) and late (24 h p.i.) times during the infective cycle, CPXV stimulated Akt at early times only. Pharmacological and genetic inhibition of PI3K (LY294002) or Akt (Akt-X and a dominant-negative form of Akt-K179M) resulted in a significant decline in virus yield (from 80% to ≥90%). This decline was secondary to the inhibition of late viral gene expression, which in turn led to an arrest of virion morphogenesis at the immature-virion stage of the viral growth cycle. Furthermore, the cleavage of both caspase-3 and poly(ADP-ribose) polymerase and terminal deoxynucleotidyl transferase-mediated deoxyuridine nick end labeling assays confirmed that permissive, spontaneously immortalized cells such as A31 cells and mouse embryonic fibroblasts (MEFs) underwent apoptosis upon orthopoxvirus infection plus LY294002 treatment. Thus, in A31 cells and MEFs, early viral receptor-mediated signals transmitted via the PI3K/Akt pathway are required and precede the expression of viral antiapoptotic genes. Additionally, the inhibition of these signals resulted in the apoptosis of the infected cells and a significant decline in viral titers.

1 November 2014 in Antiviral Research
Verified
Journal Article
Closed access
JAJonas Dutra Albarnaz
Jonas Dutra Albarnaz
LOLeonardo C. De Oliveira
Leonardo C. De Oliveira
ATAlice Torres
Alice Torres
RPRafael M. Palhares
Rafael M. Palhares
MCMarisa C. Casteluber
Marisa C. Casteluber
CBCláudio Bonjardim
Cláudio Bonjardim

23 December 2021 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
JAJonas Dutra Albarnaz
Jonas Dutra Albarnaz
HRHongwei Ren
Hongwei Ren
ATAlice Torres
Alice Torres
ESEvgeniya V. Shmeleva
Evgeniya V. Shmeleva
CMCarlos A. Melo
Carlos A. Melo
GSGeoffrey L. Smith
Geoffrey L. Smith

28 February 2018 in Viruses
Verified
Journal Article
Open access
PDF file
JAJonas Dutra Albarnaz
Jonas Dutra Albarnaz
ATAlice Torres
Alice Torres
GSGeoffrey L. Smith
Geoffrey L. Smith
The increasing frequency of monkeypox virus infections, new outbreaks of other zoonotic orthopoxviruses and concern about the re-emergence of smallpox have prompted research into developing antiviral drugs and better vaccines against these viruses. This article considers the genetic engineering of vaccinia virus (VACV) to enhance vaccine immunogenicity and safety. The virulence, immunogenicity and protective efficacy of VACV strains engineered to lack specific immunomodulatory or host range proteins are described. The ultimate goal is to develop safer and more immunogenic VACV vaccines that induce long-lasting immunological memory.

1 September 2016 in Cellular Signalling
Verified
Journal Article
Closed access
HHHugo W. Huth
Hugo W. Huth
JAJonas Dutra Albarnaz
Jonas Dutra Albarnaz
ATAlice Torres
Alice Torres
CBClaudio A. Bonjardim
Claudio A. Bonjardim
CRCatherine ROPERT
Catherine ROPERT